Our mission is to develop an antibiotic called Cethromycin for relapsing dormant liver stage malaria and/or for malaria prophylaxis. The drug candidate we are developing has already been through extensive clinical testing for community acquired pneumonia but was never approved based on lack of superiority over existing pneumonia drugs.

Because Cethromycin has already been safely used in 500 human patients, we plan to quickly place it into phase 2 clinical trials for malaria while still following the traditional 505(b)(1) New Drug Application (NDA) regulatory pathway. This shorter drug development program requires less resources and is less risky than developing completely new compounds from scratch.